Home » CYTRX PROVIDES 2006 UPDATE ON RNAI-BASED DRUG DISCOVERY PROGRAMS
CYTRX PROVIDES 2006 UPDATE ON RNAI-BASED DRUG DISCOVERY PROGRAMS
CytRx Corporation today reported substantial
progress in its drug discovery programs aimed at using its proprietary RNA interference
(RNAi) technologies to develop novel molecular medicines to treat obesity and
type 2 diabetes. "During the past year, CytRx-sponsored research programs
have discovered and validated approximately 30 new type 2 diabetes and obesity
drug targets through the use of our high throughput functional RNAi screening
platform.
Yahoo
News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May